Global Managed Access Program (MAP) Cohort to Provide Access to Ligelizumab (QGE031) for Chronic Spontaneous Urticaria (CSU).
Latest Information Update: 19 May 2022
At a glance
- Drugs Ligelizumab (Primary)
- Indications Chronic urticaria
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 06 May 2022 Status changed from recruiting to completed.
- 01 Jun 2021 New trial record